Authors: Canan Eroğlu Mücahit Seçme Pelin Atmaca Oğuzhan Kaygusuz Kutret Gezer Gülseren Bağcı Yavuz Dodurga
Publish Date: 2016/01/28
Volume: 68, Issue: 5, Pages: 2075-2081
Abstract
In this study in order to investigate the anticancer mechanism of Calvatia gigantea extract edible mushroom species which belong to Lycoperdaceae family changes of CCND1 CCND2 CDK4 p21 Akt Bax Bcl2 p53 caspase3 and caspase9 were evaluated in A549 lung cancer cells Cytotoxic effect of C gigantea extract was evaluated by using XTT 23bis2methoxy4nitro5sulfophenyl2Htetrazolium5 carboxanilide The C gigantea extract was treated in a time and dose dependent manner within the range 25 μg/ml–2 mg/ml to determine the IC50 dose IC50 dose for C gigantea extract was detected as 500 μg/ml for 72 h According to expression results while CCND1 CCND2 CDK4 Akt and Bcl2 expression clearly decreased Bax p53 caspase3 and caspase9 expression clearly increased in the dose group cells A549 cells treated with 500 μg/ml dose of C gigantea extract for 72 h However there was no change in p21 expression C gigantea extract induced cell cycle arrest and apoptosis by decreasing the CCND1 CCND2 CDK4 Akt and Bcl2 expression and by increasing Bax p53 caspase3 and caspase9 expression in A549 cells Mushrooms are eukaryotic organisms heavily used because of their supposedly anticancer effect Many mushroom species have been used for medical purposes as a result of also having many effects such as antibiotic antiviral and anticancer effects It is thought that the C gigantea extract may be a significant agent for treatment of lung cancer as a single agent or in combination with other drugs
Keywords: